Renaissance Technologies's TEVA Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 1.0M shares of Teva Pharmaceutical Industries Limited (TEVA) worth $20.25 M, representing 0.03% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in TEVA, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2019, adding 7.2M shares. Largest reduction occurred in Q4 2019, reducing 4.7M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +298,364 | Add 0.00% | 298,363 | $39.20 |
| Q3 2013 | -298,363 | Sold Out | 298,363 | $0.00 |
| Q2 2014 | +504,663 | New Buy | 504,663 | $52.42 |
| Q3 2014 | -239,800 | Reduce 47.52% | 264,863 | $53.75 |
| Q4 2014 | +699,800 | Add 264.21% | 964,663 | $57.51 |
| Q1 2015 | +374,300 | Add 38.80% | 1.34 M | $62.30 |
| Q2 2015 | +736,800 | Add 55.03% | 2.08 M | $59.10 |
| Q3 2015 | +803,000 | Add 38.68% | 2.88 M | $56.46 |
| Q4 2015 | -2.35 M | Reduce 81.50% | 532,500 | $65.64 |
| Q1 2016 | +658,763 | Add 123.71% | 1.19 M | $53.51 |
| Q2 2016 | +196,500 | Add 16.50% | 1.39 M | $50.23 |
| Q3 2016 | +560,200 | Add 40.37% | 1.95 M | $46.01 |
| Q4 2016 | +217,900 | Add 11.19% | 2.17 M | $36.25 |
| Q1 2017 | +2.65 M | Add 122.44% | 4.82 M | $32.09 |
| Q2 2017 | -4.82 M | Sold Out | 4.82 M | $0.00 |
| Q1 2018 | +900,963 | New Buy | 900,963 | $17.09 |
| Q2 2018 | +3.14 M | Add 348.06% | 4.04 M | $24.32 |
| Q3 2018 | -567,200 | Reduce 14.05% | 3.47 M | $21.54 |
| Q4 2018 | +3.47 M | Add 100.08% | 6.94 M | $15.42 |
| Q1 2019 | -4.32 M | Reduce 62.17% | 2.63 M | $15.68 |
| Q2 2019 | +7.16 M | Add 272.64% | 9.79 M | $9.23 |
| Q3 2019 | -2.85 M | Reduce 29.10% | 6.94 M | $6.88 |
| Q4 2019 | -4.71 M | Reduce 67.83% | 2.23 M | $9.80 |
| Q1 2020 | +967,036 | Add 43.33% | 3.2 M | $8.98 |
| Q2 2020 | +892,431 | Add 27.90% | 4.09 M | $12.33 |
| Q3 2020 | -2.95 M | Reduce 72.16% | 1.14 M | $9.01 |
| Q4 2020 | -1.14 M | Sold Out | 1.14 M | $0.00 |
| Q2 2021 | +946,363 | New Buy | 946,363 | $9.90 |
| Q3 2021 | -910,563 | Reduce 96.22% | 35,800 | $9.75 |
| Q4 2021 | +929,397 | Add 2596.08% | 965,197 | $8.01 |
| Q1 2022 | +1.62 M | Add 168.25% | 2.59 M | $9.39 |
| Q2 2022 | +1.56 M | Add 60.09% | 4.14 M | $7.52 |
| Q3 2022 | +195,037 | Add 4.71% | 4.34 M | $8.07 |
| Q4 2022 | +250,563 | Add 5.77% | 4.59 M | $0.01 |
| Q1 2023 | +1.94 M | Add 42.35% | 6.53 M | $0.01 |
| Q2 2023 | +5,400 | Add 0.08% | 6.54 M | $0.01 |
| Q3 2023 | -2.52 M | Reduce 38.56% | 4.02 M | $10.20 |
| Q4 2023 | +1.42 M | Add 35.28% | 5.44 M | $10.44 |
| Q1 2024 | +2.26 M | Add 41.61% | 7.7 M | $14.11 |
| Q2 2024 | +1.03 M | Add 13.40% | 8.73 M | $16.25 |
| Q3 2024 | -615,600 | Reduce 7.05% | 8.11 M | $18.02 |
| Q4 2024 | -1.14 M | Reduce 14.01% | 6.98 M | $22.04 |
| Q1 2025 | -1.67 M | Reduce 24.01% | 5.3 M | $15.37 |
| Q2 2025 | -2.14 M | Reduce 40.45% | 3.16 M | $16.76 |
| Q3 2025 | -2.15 M | Reduce 68.24% | 1 M | $20.20 |
Renaissance Technologies's Teva Pharmaceutical Industries Limited Investment FAQs
Renaissance Technologies first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q2 2013, acquiring 298,363 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Teva Pharmaceutical Industries Limited (TEVA) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q2 2019, adding 9,786,063 shares worth $90.32 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 1,002,545 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $20.25 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 0.03% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 9,786,063 shares, as reported at the end of Q2 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.